Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 62,820,000 $ 77,404,000
Accounts receivable - trade 207,000 426,000
Settlement receivable - current portion 5,100,000 5,100,000
Investments in debt securities 19,453,000 19,570,000
Inventory 587,000 27,000
Prepaid expenses and other current assets 1,650,000 2,070,000
Total Current Assets 89,817,000 104,597,000
Convertible promissory note receivable and accrued interest 1,575,000 1,556,000
Settlement receivable - noncurrent portion 5,100,000 5,100,000
Finance lease right-of-use assets, net of accumulated amortization 25,695,000 26,111,000
Operating lease right-of-use asset 3,487,000 0
Equity Securities, FV-NI 1,760,000 0
Fixed assets, net of accumulated depreciation 9,821,000 8,628,000
Intangible assets, net of accumulated amortization 5,164,000 952,000
Prepaid expenses - noncurrent 1,296,000 0
Security deposits 24,000 24,000
Total Assets 143,739,000 146,968,000
Current liabilities:    
Accounts payable 2,292,000 2,254,000
Accrued expenses (related party of $840 and $701 as of September 30, 2021 and June 30, 2021, respectively) 2,691,000 3,001,000
Acquisition Payable 2,500,000 0
Finance lease obligations - current portion 374,000 367,000
Operating lease obligation - current portion 147,000 0
Note payable - PPP loan - current portion 0 600,000
Deferred revenue / Contract liabilities 94,000 423,000
Total Current Liabilities 8,098,000 6,645,000
Finance lease obligations - net of current portion 31,660,000 31,755,000
Operating lease obligation - net of current portion 3,456,000 0
Total Liabilities 43,214,000 38,400,000
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2021 and June 30, 2021; 217,957,594 and 217,873,094 shares issued and outstanding as of September 30, 2021 and June 30, 2021, respectively 217,000 217,000
Additional paid-in capital 282,956,000 282,058,000
Accumulated other comprehensive loss (64,000) (63,000)
Accumulated deficit (182,566,000) (173,627,000)
Total iBio, Inc. Stockholders' Equity 100,543,000 108,585,000
Noncontrolling interest (18,000) (17,000)
Total Equity 100,525,000 108,568,000
Total Liabilities and Equity $ 143,739,000 $ 146,968,000